景凱生物科技股份有限公司

26/12/2019

本公司榮獲2019年第十六屆國家新創獎-企業新創獎

「治療慢性肝發炎之新穎藥物」該項技術為長效小分子口服藥物TLR4拮抗劑之老藥新用，以肝臟慢性疾病為目標，開發臨床疾病未達醫療需求之適應症NASH，目前與恒翼生物醫藥科技(上海)有限公司(NEWSOARA BIOPHARMA CO., LTD)簽署JKB-122新藥獨家授權亞洲市場開發，並持續發展其它相關項目。
https://innoaward.taiwan-healthcare.org/data/tmp/20191210/20191210nb3oqh.jpg

11/03/2019

TaiwanJ Pharmaceuticals Obtained US$26M Deal for Licensing and Co-Development Contract with Newsoara Biopharma on JKB-122 Asian Rights

https://www.prnewswire.com/news-releases/taiwanj-pharmaceuticals-obtained-us26m-deal-for-licensing-and-co-development-contract-with-newsoara-biopharma-on-jkb-122-asian-rights-300809104.html

HSINCHU, Taiwan, March 8, 2019 /PRNewswire/ -- TaiwanJ Pharmaceuticals has signed a US$26 million contract with Newsoara Biopharma to license out its drug...

04/03/2019

景凱與恒翼生物醫藥科技(上海)有限公司簽訂JKB-122及JKB-133授權合約
http://taiwanj.com/articles/article_view_tw/1021

景凱生技

22/01/2019

TaiwanJ Pharmaceuticals Announces Positive Results from Phase 2 Orphan Drug Designation Study of JKB-122 on Autoimmune Hepatitis (AIH)

http://www.prnewswire.com/news-releases/taiwanj-pharmaceuticals-announces-positive-results-from-phase-2-orphan-drug-designation-study-of-jkb-122-on-autoimmune-hepatitis-aih-300781770.html?tc=eml_cleartime

HSINCHU, Taiwan, Jan. 21, 2019 /PRNewswire/ -- TaiwanJ Pharmaceuticals, a specialty pharmaceutical company dedicated to the development and commercialization...

31/10/2018

TaiwanJ Pharmaceuticals Announces Positive Top-Line Results from Phase 2 Study of JKB-122 on Non-Alcoholic Fatty Liver Disease (NAFLD)

https://www.prnewswire.com/news-releases/taiwanj-pharmaceuticals-announces-positive-top-line-results-from-phase-2-study-of-jkb-122-on-non-alcoholic-fatty-liver-disease-nafld-300736852.html?tc=eml_cleartime

21/02/2018

景凱生技治療自體免疫性肝炎(AIH)新藥JKB-122 二期臨床試驗已達到收案目標

http://www.taiwanj.com/articles/article_view_tw/1016

景凱生技

26/12/2017

女性創業賽》景凱生技 助人小心「肝」

https://money.udn.com/money/story/5635/2893841

「女力」抬頭！現今有愈來愈多女性創業家嶄露頭角，鋒芒四射。經濟部中小企業處主辦的「女性創業菁英賽」今年邁入第六屆，經濟日報特選「菁英組」獲獎女性企業，報導經營故事，以饗讀者，也為眾多在各地積極努力的優

20/12/2017

景凱生技非酒精性脂肪肝病(NAFLD)新藥JKB-122二期臨床試驗已達收案目標

http://www.taiwanj.com/articles/article_view_tw/1015

02/11/2017

恭賀石英珠Ying-Chu Shih董事長代表景凱生技參加「第六屆女性創業菁英賽」菁英組評選，榮獲【菁英組佳作獎】。由經濟部中小企業處主辦的第六屆女性創業菁英賽，為表彰女性創業成功典範，本次全國有121件參賽，共28家女性企業獲獎，其中【菁英組】以「曾獲國內外獎項肯定、政府創新補助，或事業體成熟度較高，並於該產業營運表現卓越之企業」為評選標準，此次獲得精英組獎項肯定景凱為實力堅強，營運表現卓越之企業。

01/09/2017

景凱生技慢性C型肝炎臨床二期試驗第一階段解盲

http://taiwanj.com/articles/article_view_tw/1016

12/07/2017

景凱於歐洲藥理學雜誌(European Journal of Pharmacology)發表JKB-122抑制自體免疫性肝炎論

論文網頁: https://doi.org/10.1016/j.ejphar.2017.07.012
中文版摘要:http://taiwanj.com/articles/article_view_tw/1016

Con A-induced hepatitis in mice is an established model of autoimmune hepatitis (AIH). JKB-122, a toll-like receptor 4 (TLR4) antagonist, was tested for hepatotprotectant activity. Within several hours of Con A challenge (15 mg/kg iv), increased production of proinflammatory cytokines with inflammat...

03/07/2017

優先國際賽局 慢性肝炎新藥下半年二期解盲 景凱攤位L530 JKB-122有望還你彩色人生
http://www.gbimonthly.com/2017/07/10842/

全球慢性型肝炎的患者約有1.3-1.5億人，是現代人最容易忽視的健康隱形殺手，慢性肝炎如果沒有接受妥善治療，將進一步造成肝纖維化甚至轉為肝癌。